Literature DB >> 9272484

Time course of 5-HT2A receptor occupancy in the human brain after a single oral dose of the putative antipsychotic drug MDL 100,907 measured by positron emission tomography.

G Gründer1, F Yokoi, S J Offord, H T Ravert, R F Dannals, J K Salzmann, S Szymanski, P D Wilson, D R Howard, D F Wong.   

Abstract

MDL 100,907 is a potent and selective antagonist of 5-HT2A serotonin receptors. Animals studies suggest that MDL 100,907 may behave as an atypical antipsychotic drug. Positron emission tomograph (PET) using [11C]NMSP as the radiotracer was used to define the time course of 5-HT2 receptor occupancy in the human frontal cerebral cortex after a single oral dose of MDL 100,907 (10 or 20 mg) in nine healthy subjects. After the baseline scan each subject was studied three times post dosing at various time points. 5-HT2 occupancies were in the range of 70 and 90% after each dose. While the occupancy remains in this range over 24 hours after 20 mg MDL 100,907, it decreases by about 20% at 24 hours compared to the timepoint at 8 hours, when only 10 mg are administered (p < 0.05). Our results should allow determination of the appropriate dosing regimen for future trials in schizophrenic patients.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9272484     DOI: 10.1016/S0893-133X(97)00044-4

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  9 in total

1.  Imaging Agonist-Induced D2/D3 Receptor Desensitization and Internalization In Vivo with PET/fMRI.

Authors:  Christin Y Sander; Jacob M Hooker; Ciprian Catana; Bruce R Rosen; Joseph B Mandeville
Journal:  Neuropsychopharmacology       Date:  2015-09-21       Impact factor: 7.853

Review 2.  Central nervous system drug development: an integrative biomarker approach toward individualized medicine.

Authors:  B Gomez-Mancilla; E Marrer; J Kehren; A Kinnunen; G Imbert; R Hillebrand; M Bergström; M E Schmidt
Journal:  NeuroRx       Date:  2005-10

3.  Characterization of the serotonin 2A receptor selective PET tracer (R)-[18F]MH.MZ in the human brain.

Authors:  Vasko Kramer; Agnete Dyssegaard; Jonathan Flores; Cristian Soza-Ried; Frank Rösch; Gitte Moos Knudsen; Horacio Amaral; Matthias M Herth
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-10-12       Impact factor: 9.236

Review 4.  "Selective" serotonin 5-HT2A receptor antagonists.

Authors:  Austen B Casey; Meng Cui; Raymond G Booth; Clinton E Canal
Journal:  Biochem Pharmacol       Date:  2022-04-04       Impact factor: 6.100

5.  Multi-graphical analysis of dynamic PET.

Authors:  Yun Zhou; Weiguo Ye; James R Brasić; Dean F Wong
Journal:  Neuroimage       Date:  2009-11-17       Impact factor: 6.556

6.  EMD 281014, a specific and potent 5HT2 antagonist in humans: a dose-finding PET study.

Authors:  David Mamo; Ewen Sedman; Joachim Tillner; Edward M Sellers; Myroslava K Romach; Shitij Kapur
Journal:  Psychopharmacology (Berl)       Date:  2004-09       Impact factor: 4.530

Review 7.  Developing therapeutics for schizophrenia and other psychotic disorders.

Authors:  Gerard Marek; Kalpana Merchant
Journal:  NeuroRx       Date:  2005-10

8.  The plasma-occupancy relationship of the novel GABAA receptor benzodiazepine site ligand, alpha5IA, is similar in rats and primates.

Authors:  John R Atack; Wai-Si Eng; Ray E Gibson; Christine Ryan; Barbara Francis; Bindi Sohal; Gerard R Dawson; Richard J Hargreaves; H Donald Burns
Journal:  Br J Pharmacol       Date:  2009-04-30       Impact factor: 8.739

Review 9.  5-HT radioligands for human brain imaging with PET and SPECT.

Authors:  Louise M Paterson; Birgitte R Kornum; David J Nutt; Victor W Pike; Gitte M Knudsen
Journal:  Med Res Rev       Date:  2011-06-14       Impact factor: 12.944

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.